Hormone therapy showdown: can an oral pill beat the shot for prostate cancer patients?

NCT ID NCT05765500

Recruiting now Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This phase 2 trial compares two standard hormone therapies for prostate cancer—relugolix (a daily pill) and leuprolide (an injection every three months)—to see how they affect quality of life, cholesterol, and blood sugar. The study enrolls men who need six months of hormone therapy and have not had this type of treatment before. Researchers will also track how quickly testosterone levels return to normal after treatment ends.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: relugolix (an oral GnRH antagonist) and leuprolide (an injectable GnRH agonist)
What this could lead to: If one drug proves better for quality of life or faster testosterone recovery, it could help men choose a hormone therapy that fits their lifestyle and health goals.
What could go wrong: This is a phase 2 study with only 110 men, so results may not apply to everyone. Both drugs are already approved, so the trial is comparing known options rather than testing a new cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER PROSTATIC NEOPLASMS

Contacts and locations

Locations

Brigham and Women's Hospital
NOT_YET_RECRUITING

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute at Foxborough
RECRUITING

Foxborough, Massachusetts, 02035, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.